Lilly Cymbalta keeps growing in pain states
This article was originally published in Pharmaceutical Approvals Monthly
FDA approval of Lilly's Cymbalta (duloxetine) for management of fibromyalgia June 16 comes on the heels of a May sNDA submission for management of chronic pain that is backed by the same trial data that supported the fibromyalgia filing. Lilly also submitted chronic pain data from three additional trials, two in chronic low back pain and one in osteoarthritis of the knee. OA of the knee data from a 231-patient trial that Lilly characterized as "the first time duloxetine has been studied in a large, placebo-controlled trial in … an inflammatory disease state" was presented to the European League Against Rheumatism annual congress in Paris June 13. On the primary efficacy measure of mean 24-hour pain score, 59 percent of duloxetine OA of the knee patients reported a 30 percent improvement in pain compared with 45 percent of placebo patients; a 50 percent improvement in pain was reported by 47 percent of duloxetine and 29 percent of placebo patients. The serotonin and norepinephrine reuptake inhibitor's expansion from its core antidepressant use was inaugurated by a diabetic neuropathic pain claim approved Sept. 3, 2004
You may also be interested in...
Exec Chat: How Edwards Lifesciences Deploys AI, Remote Monitoring To Help Doctors Make Life-Critical Decisions
Edwards Lifesciences’ head of critical care expects that “smart recovery” AI-driven products will grow the fastest in its critical care unit, which is expected to reach $800m in total revenues for 2021.
I.V. Korsuva now has an August FDA action date, which partner Vifor would commercialize in the ESRD dialysis setting while Cara works toward a broad anti-pruritus label for its oral tablet formulation.
China, Iran and especially Russia have launched campaigns aimed at undermining confidence in Western vaccines, especially Pfizer’s, according to two reports.